Asia-Pacific Active Pharmaceutical Ingredients (API) Market, By Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS & Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Market Analysis and Insights: Asia-Pacific Active Pharmaceutical Ingredients (API) Market
The active pharmaceutical ingredients (API) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.5% in the forecast period of 2021 to 2028 and is expected to reach USD 86,222.48 million by 2028. Increasing prevalence of various chronic disorders and increase in aging population are the major drivers which propelled the demand of the active pharmaceutical ingredients (API) market in the forecast period.
- In Greek, the traditional word for active pharmaceutical ingredients (API) is called pharmacon or pharmakon which symbolizes a magical substance or drug. Active pharmaceutical ingredients as described in ICH Q7 are “any substance or combination of substances intended to be used in the manufacturing of a drug product which when used in the production of the drug becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity.
Increase in technological advancements will enhance the capabilities and boost the manufacturing skills of the market players that the manufacturers have to provide APIs in bulk and meet the demand of the consumers which can drive the growth of the active pharmaceutical ingredients (API) market. Availability of sub-standard and counterfeit drugs is acting as a restraint for hampering the demand of the active pharmaceutical ingredients (API) market. Rising investment in research regarding the development of APIs will further increase the growth opportunities for the active pharmaceutical ingredients (API) market. Disruption in the supply chain of APIs during COVID-19 acts challenging for the healthcare providers which may challenge the active pharmaceutical ingredients (API) market.
The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Active Pharmaceutical Ingredients (API) Market Scope and Market Size
The active pharmaceutical ingredients (API) market is segmented on the basis of the molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of molecule, the active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power.
- On the basis of type, the active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities.
- On the basis of type of manufacturer, the active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. In 2021, captive API manufacturer segment is expected to dominate the active pharmaceutical ingredients (API) market due to huge investment by major market players to generate high end manufacturing facilities and easy availability of raw materials.
- On the basis of synthesis, the active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients. In 2021, synthetic active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines and in the coming years, many synthetic molecules goes off patent.
- On the basis of chemical synthesis, the active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen and others. In 2021, saxagliptin segment is expected to dominate the active pharmaceutical ingredients (API) market due to high cost of the API and rising diabetes cases worldwide.
- On the basis of type of drug, the active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2021, prescription drugs segment is dominating the active pharmaceutical ingredients (API) market because of high cost of the drugs which will increase the APIs and manufacturing cost of the APIs.
- On the basis of usage, the active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2021, clinical segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of diseases which required continuous supply of APIs and raw material.
- On the basis of potency, the active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient. In 2021, low-to-moderate potency active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of their less toxicity and less hazard nature.
- On the basis of therapeutic application, the active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and other therapeutic application. In 2021, cardiology segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of cardiac diseases such as heart attack, embolism and others.
Active Pharmaceutical Ingredients (API) Market Country Level Analysis
The active pharmaceutical ingredients (API) market is analyzed and market size information is provided on the basis of the country, molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application as referenced above.
The countries covered in the Asia-Pacific active pharmaceutical ingredients (API) market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.
China is dominating in the Asia-Pacific active pharmaceutical ingredients (API) market owing to government initiatives for the production of APIs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Prevalence of Various Chronic Disorders is boosting the Growth of Active Pharmaceutical Ingredients (API) Market
The active pharmaceutical ingredients (API) market also provides you with detailed market analysis for every country growth in active pharmaceutical ingredients (API) industry with active pharmaceutical ingredients (API) drugs sales, impact of advancement in the active pharmaceutical ingredients (API) technology and changes in regulatory scenarios with their support for the active pharmaceutical ingredients (API) market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Active Pharmaceutical Ingredients (API) Market Share Analysis
The active pharmaceutical ingredients (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to active pharmaceutical ingredients (API) market.
The major companies which are dealing in the active pharmaceutical ingredients (API) are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB,Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, , AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., Viatris Inc. , Merck KGaA, Novo Nordisk A/S, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., BASF SE, Piramal Pharma Solutions, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the active pharmaceutical ingredients (API) market.
For instance,
- In December 2019, AbbVie Inc. collaborated with Scripps Research in order to boost up the research for new drug discovery targeting a range of diseases, including areas on oncology, immunology among others. As per the collaboration agreement Scripps Research will conduct the pre-clinical research activities for development of novel therapies. This collaboration helped the company to advance up its novel medicines for patients that has ultimately boosted company’s revenue.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the active pharmaceutical ingredients (API) market which also provides the benefit for organization to improve their offering for active pharmaceutical ingredients (API).
SKU-